In the realm of personalized healthcare, Eversens SL stands as a beacon of innovation, harnessing the power of breath analysis to unlock profound insights into human health. Founded in Pamplona, Spain, Eversens is a leader in developing innovative solutions based on exhaled biomarker analysis.

Their flagship product, the evernoa BASE device, represents a paradigm shift in respiratory health monitoring. This compact, user-friendly device allows individuals to assess their airway inflammation levels simply by exhaling into a mouthpiece. The evernoa BASE utilizes patented technology to detect nitric oxide (NO), a biomarker closely associated with asthma and other respiratory conditions.

The simplicity and non-invasiveness of the evernoa BASE make it an ideal tool for both healthcare providers and individuals seeking personalized insights into their respiratory health. By regularly monitoring NO levels, individuals can proactively manage their symptoms, optimize medication compliance, and identify potential exacerbations early on.

Eversens’ commitment to innovation extends beyond diagnostic tool development. They are actively involved in research and development, exploring the potential of exhaled biomarkers to address a broader spectrum of health conditions. Their research aims to establish breath analysis as a reliable and accessible method for early disease detection, personalized treatment, and disease management.

With a team of passionate experts dedicated to advancing breath analysis, Eversens is shaping the future of personalized healthcare. Their vision is to empower individuals to take control of their health by providing actionable insights from their breath. As Eversens continues to refine its technologies and expand its research, the potential of breath analysis to revolutionize healthcare is limitless.